Dates: March 5-9, 2025
Location: Vienna International Centre (VIC), Vienna, Austria
Organizer: Kenes Group
Website: adpd.kenes.com
AD/PD 2025 was held in Vienna, Austria, continuing the tradition of bringing together Alzheimer's and Parkinson's disease researchers in a unique integrated format. The conference is distinguished by its focus on the mechanistic links between AD and PD, exploring common pathways and shared therapeutic approaches.
¶ Amyloid and Tau Biology
- Amyloid-beta aggregation mechanisms and toxic species identification
- Tau phosphorylation patterns and spread patterns
- Amyloid-Tau interaction effects on neurodegeneration
- Post-translational modifications affecting protein aggregation
- Microglial biology in AD pathogenesis
- Complement cascade involvement in synaptic dysfunction
- Astrocyte reactivity and neurotransmitter modulation
- Peripheral immune system interactions with CNS
- Fluid biomarkers (p-tau, NfL, GFAP) clinical implementation
- PET imaging advances for amyloid, tau, and neuroinflammation
- Digital biomarkers for remote monitoring
- Multimodal biomarker panels for disease staging
- Anti-amyloid antibody outcomes and real-world data
- Tau-targeted therapy progress
- Disease-modifying approaches in early AD
- Prevention trials in at-risk populations
- Alpha-synuclein (/proteins/alpha-synuclein) aggregation mechanisms
- Prion-like spreading of pathological species
- Strain diversity and clinical phenotypes
- Antibody trials targeting alpha-synuclein
- LRRK2 (/genes/lrrk2) variants and kinase inhibition
- GBA (/genes/gba) mutations and Gaucher disease link
- SNCA (/genes/snca) multiplication and overexpression
- PARKIN (/genes/parkin) and mitochondrial dysfunction
- Deep brain stimulation advances
- Levodopa-carbidopa intestinal gel outcomes
- Novel dopaminergic agents
- Non-motor symptoms management
- Neuroinflammation as common pathway
- Mitochondrial dysfunction in both AD and PD
- Oxidative stress and protein aggregation
- Lysosomal/autophagy impairment
- Neurofilament light chain (NfL) as progression marker
- p-tau217 in Lewy body disease
- Alpha-synuclein seeding assays in AD
- Neuroinflammation markers across diseases
- Multi-target therapeutic strategies
- Sequential intervention timing
- Personalized medicine based on biomarker profiles
- "Alpha-Synuclein and Amyloid: Shared Pathways, Shared Therapies"
- "Neuroinflammation in AD and PD: Common Mechanisms"
- "Biomarker Convergence: What Tells Us About Both Diseases"
- Tau Imaging Workshop — Advanced PET analysis methods
- Alpha-Synuclein Seed Assay — Clinical implementation challenges
- Clinical Trial Design — Optimizing for disease modification
- Results from Phase 3 anti-amyloid trials
- LRRK2 inhibitor clinical outcomes
- α-synuclein antibody trial results
- Genetic risk modifier studies
The Vienna International Centre (VIC) is one of the world's major conference centers, hosting numerous scientific meetings annually. The venue offers state-of-the-art facilities for scientific presentations.
Vienna is home to several leading research institutions:
- Medical University of Vienna — Major AD/PD research programs
- University of Vienna — Basic neuroscience research
- Austrian Academy of Sciences — Neurological research
- IMP Vienna — Molecular biology research
Vienna combines historic charm with scientific excellence:
- Historic center (Innere Stadt) is a UNESCO World Heritage site
- Excellent public transportation system
- Central European location accessible from many countries
- Rich cultural offerings including music, art, and architecture